Latest Expert Exchange Queries
sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
 
 
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Service Tax | Sales Tax | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Indirect Tax | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing
 
 
 
 
Popular Search: VAT RATES :: cpt :: form 3cd :: TAX RATES - GOODS TAXABLE @ 4% :: articles on VAT and GST in India :: VAT Audit :: TDS :: ACCOUNTING STANDARD :: list of goods taxed at 4% :: due date for vat payment :: Central Excise rule to resale the machines to a new company :: empanelment :: ICAI offer Get Windows 7,Office 2010 in Rs.799 Taxes :: ACCOUNTING STANDARDS :: ARTICLES ON INPUT TAX CREDIT IN VAT
 
 
« News Headlines »
 How to file income-tax returns online
 How Income Tax Returns Are Scrutinised
 All About New Income Disclosure Scheme to make Demonetisation successful
 Your deposit may draw income tax notice
 Accepting payment under IDS 2016
 New disclosure scheme could see 50% tax and 4-year limit on cash use for unaccounted deposits
 Pay 50% tax on unaccounted deposits, or 85% if caught, says Modi government
 Deadline to pay property tax in old currency extended
 Cabinet clears amendments to Income Tax Act
 Have you got interest on your income tax refund?
 New income tax rules to curb unaccounted cash

Fee paid to Canadian co for clinical studies not taxable in India
September, 24th 2008

Fees for clinical bioanalytical studies paid by Indian pharmaceutical companies to foreign research bodies are not taxable in India, the Authority for Advance Rulings (AAR), a quasi-judicial authority, has ruled. AAR gave this ruling on an appeal filed by a Canadian company Anapharm. It said the fees it received from the Indian pharma companies does not amount to fees for included services or royalties under article 12 of the India Canada Double Taxation Avoidance Agreement (DTAA).

Anapharm, a contract research organisation in Canada had formed agreements with Sandoz and Ranbaxy Research Laboratories for rendering clinical and bioanalytical services to assist them in the development of new drugs or for generic copies of drugs.

Both companies paid the fees for Anapharms services. The issue before AAR was whether such payments are liable to be taxed in India. AAR held that such payments are in the nature of business profits and hence not taxable in India. The authority considered the absence of a permanent establishment in India for Anapharm, a requirement for being taxed in India on business profits.

The Income-tax department claimed that Anapharm had imparted a service involving technology, knowhow, skill and experience which would result in the Indian companies having exclusive right over the result of the project which may include new products, technology, patents, tested samples etc. Therefore these transactions have the character of fee for technical services and royalty which are liable to be taxed in India.

AAR held that that providing a service requiring technical input does not imply that the technical knowledge and skills are made available to the person buying the service, within the meaning of the India-Canada DTAA. Also, use of a product that embodies technology does not imply that technology is made available. Payment would be regarded as fee for technical/included services only if the twin test of rendering services and making technical knowledge available at the same time, was satisfied.

Anapharms submission before AAR was as follows: There was no transfer of technology, technical plan, design, or knowhow to the Indian companies, a basic requirement to attract article 12 of the Treaty which emphasises on the word make available. Therefore the payments could not classified under the head fees for included services under the Treaty.

Technology was made available to the Indian companies only when they were equipped to apply that technology. Since Anapharm did not pass, reveal or transfer any knowhow or technology or skill to the Indian companies, such payment cannot be construed as royalty fees, which can attract tax in India.

 
 
Home | About Us | Terms and Conditions | Contact Us
Copyright 2016 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Multimedia Presentations Multimedia Solutions 3D Solutions Corporate Presentations Business Presentations Multimedia Presentation India M

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions